222 related articles for article (PubMed ID: 22038993)
1. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
[TBL] [Abstract][Full Text] [Related]
2. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
3. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
5. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Franssen GM; Versleijen-Jonkers YM; Oyen WJ; van der Graaf WT; Boerman OC
J Nucl Med; 2010 Oct; 51(10):1565-72. PubMed ID: 20847162
[TBL] [Abstract][Full Text] [Related]
6. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
9. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
[TBL] [Abstract][Full Text] [Related]
11. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
12. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
[TBL] [Abstract][Full Text] [Related]
14. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of IGF-1R expression during endocrine breast cancer treatment.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Koornstra RH; Linn SC; Oyen WJ; van der Graaf WT; van Laarhoven HW
Mol Imaging Biol; 2014 Aug; 16(4):529-37. PubMed ID: 24532107
[TBL] [Abstract][Full Text] [Related]
17. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
Cornelissen B; McLarty K; Kersemans V; Reilly RM
Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
[TBL] [Abstract][Full Text] [Related]
18. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
